JP2009502801A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502801A5 JP2009502801A5 JP2008522958A JP2008522958A JP2009502801A5 JP 2009502801 A5 JP2009502801 A5 JP 2009502801A5 JP 2008522958 A JP2008522958 A JP 2008522958A JP 2008522958 A JP2008522958 A JP 2008522958A JP 2009502801 A5 JP2009502801 A5 JP 2009502801A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- hydrogen
- heteroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 147
- 125000003118 aryl group Chemical group 0.000 claims 135
- 125000001072 heteroaryl group Chemical group 0.000 claims 134
- 229910052739 hydrogen Inorganic materials 0.000 claims 114
- 239000001257 hydrogen Substances 0.000 claims 109
- 150000002431 hydrogen Chemical class 0.000 claims 98
- 125000004404 heteroalkyl group Chemical group 0.000 claims 66
- 150000001875 compounds Chemical class 0.000 claims 61
- 125000002252 acyl group Chemical group 0.000 claims 54
- 238000010276 construction Methods 0.000 claims 41
- 125000000623 heterocyclic group Chemical group 0.000 claims 39
- 229910052736 halogen Inorganic materials 0.000 claims 34
- 150000002367 halogens Chemical class 0.000 claims 34
- 125000004432 carbon atom Chemical group C* 0.000 claims 26
- 229910052757 nitrogen Inorganic materials 0.000 claims 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims 20
- 125000002947 alkylene group Chemical group 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 19
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 18
- -1 heteroaliphatic Chemical group 0.000 claims 17
- 229940079593 drug Drugs 0.000 claims 16
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 16
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 9
- 125000002723 alicyclic group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- 125000001931 aliphatic group Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000001544 thienyl group Chemical group 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- 102000003989 Aurora kinases Human genes 0.000 claims 3
- 108090000433 Aurora kinases Proteins 0.000 claims 3
- 208000020084 Bone disease Diseases 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000019838 Blood disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 230000001066 destructive effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 229940124622 immune-modulator drug Drugs 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229940124589 immunosuppressive drug Drugs 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000003900 neurotrophic factor Substances 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical group C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000005431 alkyl carboxamide group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000005441 aurora Substances 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000005518 carboxamido group Chemical group 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- CWJSHJJYOPWUGX-UHFFFAOYSA-N chlorpropham Chemical compound CC(C)OC(=O)NC1=CC=CC(Cl)=C1 CWJSHJJYOPWUGX-UHFFFAOYSA-N 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 125000005432 dialkylcarboxamide group Chemical group 0.000 claims 1
- 125000005363 dialkylsulfonamide group Chemical group 0.000 claims 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 125000004963 sulfonylalkyl group Chemical group 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 125000004001 thioalkyl group Chemical group 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 0 *[n]1ncc2c1c(I)ncn2 Chemical compound *[n]1ncc2c1c(I)ncn2 0.000 description 23
- QOHLCRQDXAPADP-UHFFFAOYSA-N C[n](cc12)nc1ncnc2I Chemical compound C[n](cc12)nc1ncnc2I QOHLCRQDXAPADP-UHFFFAOYSA-N 0.000 description 1
- OEKDTBVYFDMOMJ-UHFFFAOYSA-N C[n]1nc2c(I)ncnc2c1 Chemical compound C[n]1nc2c(I)ncnc2c1 OEKDTBVYFDMOMJ-UHFFFAOYSA-N 0.000 description 1
- MRGDQLPHEVJGLS-UHFFFAOYSA-N C[n]1nc2c([IH]C)ncnc2c1 Chemical compound C[n]1nc2c([IH]C)ncnc2c1 MRGDQLPHEVJGLS-UHFFFAOYSA-N 0.000 description 1
- MRBIJHKBSSAEBT-UHFFFAOYSA-N Cc1ncnc2n[n](C)cc12 Chemical compound Cc1ncnc2n[n](C)cc12 MRBIJHKBSSAEBT-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70169505P | 2005-07-22 | 2005-07-22 | |
| PCT/US2006/028154 WO2007013964A1 (en) | 2005-07-22 | 2006-07-21 | Pyrazolo pyrimidines useful as aurora kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009502801A JP2009502801A (ja) | 2009-01-29 |
| JP2009502801A5 true JP2009502801A5 (enExample) | 2009-09-10 |
Family
ID=37102131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522958A Pending JP2009502801A (ja) | 2005-07-22 | 2006-07-21 | Ａｕｒｏｒａキナーゼインヒビターとして有用なピラゾロピリミジン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7932257B2 (enExample) |
| EP (1) | EP1915377A1 (enExample) |
| JP (1) | JP2009502801A (enExample) |
| AU (1) | AU2006272876A1 (enExample) |
| CA (1) | CA2615946A1 (enExample) |
| WO (1) | WO2007013964A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009241469B2 (en) * | 2008-04-30 | 2015-05-07 | National Health Research Institutes | Fused bicyclic pyrimidine compounds as Aurora kinase inhibitors |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| US9006252B2 (en) | 2008-09-26 | 2015-04-14 | National Health Research Institutes | Fused multicyclic compounds as protein kinase inhibitors |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| WO2013014052A1 (en) | 2011-07-22 | 2013-01-31 | Glaxosmithkline Llc | Composition |
| IN2014DN07224A (enExample) | 2012-02-03 | 2015-04-24 | Basf Se | |
| IN2014DN07954A (enExample) | 2012-03-13 | 2015-05-01 | Basf Se | |
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9173872B2 (en) | 2012-08-24 | 2015-11-03 | Glaxosmithkline Llc | Pyrazolopyrimidine compounds |
| SMT201700378T1 (it) | 2012-11-20 | 2017-09-07 | Glaxosmithkline Llc | Nuovi composti |
| KR20150085081A (ko) | 2012-11-20 | 2015-07-22 | 글락소스미스클라인 엘엘씨 | 신규 화합물 |
| JP6216387B2 (ja) | 2012-11-20 | 2017-10-18 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 新規化合物 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| CA2923101A1 (en) | 2013-09-16 | 2015-03-19 | Basf Se | Fungicidal pyrimidine compounds |
| WO2015036059A1 (en) | 2013-09-16 | 2015-03-19 | Basf Se | Fungicidal pyrimidine compounds |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| TWI853814B (zh) | 2018-05-31 | 2024-09-01 | 南韓商Ｃ＆Ｃ新藥研究所 | 雜環衍生物及其用途 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2980677A (en) | 1961-04-18 | Certificate of correction | ||
| FR2699176B1 (fr) | 1992-12-11 | 1995-03-03 | Adir | Nouveaux composés bicycliques de pyrimidine, leur procédé de préparation et les compositions pharmaceutiques les renfermant. |
| US6043228A (en) | 1993-06-08 | 2000-03-28 | Cancer Research Campaign Technology Limited | O6 -substituted guanine derivatives, a process for their preparation and their use in treating tumor cells |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| US5929046A (en) | 1994-06-08 | 1999-07-27 | Cancer Research Campaign Technology Limited | Pyrimidine and purine derivatives and their use in treating tumour cells |
| CA2240439A1 (en) | 1995-12-22 | 1997-07-03 | The Dupont Merck Pharmaceutical Company | Novel integrin receptor antagonists |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| US20010007867A1 (en) | 1999-12-13 | 2001-07-12 | Yuhpyng L. Chen | Substituted 6,5-hetero-bicyclic derivatives |
| PL332040A1 (en) | 1996-08-28 | 1999-08-16 | Pfizer | Substitution 6,5-heterobicyclic derivatives |
| US5723608A (en) | 1996-12-31 | 1998-03-03 | Neurogen Corporation | 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands |
| WO1998043962A1 (en) | 1997-03-28 | 1998-10-08 | Du Pont Pharmaceuticals Company | Heterocyclic integrin inhibitor prodrugs |
| US6531475B1 (en) | 1998-11-12 | 2003-03-11 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| EP1161431A4 (en) | 1999-03-10 | 2002-04-24 | Merck & Co Inc | 6-AZAINDOL COMPOUNDS AS AN ANTAGONISTS OF THE GONADOTROPIN RELEASE HORMONES |
| CA2367130A1 (en) | 1999-03-10 | 2000-09-14 | Merck & Co., Inc. | 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| AU7738000A (en) | 1999-09-30 | 2001-04-30 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
| US20030187261A1 (en) | 2000-01-07 | 2003-10-02 | Libor Havlicek | Purine derivatives, process for their preparation and use thereof |
| ATE446093T1 (de) | 2001-12-24 | 2009-11-15 | Astrazeneca Ab | Substituierte chinazolin-derivate als aurora- kinase inhibitoren |
| ATE478872T1 (de) | 2002-03-28 | 2010-09-15 | Ustav Ex Botan Av Cr V V I I O | Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung |
| JP2005536517A (ja) * | 2002-07-23 | 2005-12-02 | スミスクライン ビーチャム コーポレーション | キナーゼインヒビターとしてのピラゾロピリミジン |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| WO2004065392A1 (en) | 2003-01-24 | 2004-08-05 | Smithkline Beecham Corporation | Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands |
| KR100824193B1 (ko) | 2003-04-29 | 2008-04-21 | 화이자 인코포레이티드 | 고혈압 치료에 유용한5,7-디아미노피라졸로[4,3-ｄ]피리미딘 |
| US7221979B2 (en) | 2003-04-30 | 2007-05-22 | Medtronic, Inc. | Methods and apparatus for the regulation of hormone release |
| ES2351624T3 (es) * | 2003-05-06 | 2011-02-08 | Ústav Experimentálni Botaniky Av Cr, V.V.I. (Institute Of Experimental Botany Academy Of Sciences Of The Czech Republic, Pro) | Pirazolo[4,3-d]pirimidinas, procedimiento para su preparación y uso. |
| KR20060056944A (ko) | 2003-07-14 | 2006-05-25 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료 |
| NZ546611A (en) | 2003-09-18 | 2010-02-26 | Conforma Therapeutics Corp | Novel heterocyclic compounds as HSP90-inhibitors |
| US7816353B2 (en) | 2003-10-24 | 2010-10-19 | Exelixis, Inc. | P70S6 kinase modulators and method of use |
| WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
| MEP8409A (en) * | 2004-06-02 | 2011-12-20 | Fused heterocyclic compound |
-
2006
- 2006-07-21 US US11/490,983 patent/US7932257B2/en not_active Expired - Fee Related
- 2006-07-21 EP EP06800152A patent/EP1915377A1/en not_active Withdrawn
- 2006-07-21 CA CA002615946A patent/CA2615946A1/en not_active Abandoned
- 2006-07-21 JP JP2008522958A patent/JP2009502801A/ja active Pending
- 2006-07-21 WO PCT/US2006/028154 patent/WO2007013964A1/en not_active Ceased
- 2006-07-21 AU AU2006272876A patent/AU2006272876A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008506714A5 (enExample) | ||
| EP3490987B1 (en) | Novel therapeutic agents for the treatment of hbv infection | |
| ES2566797T3 (es) | Compuestos de polímero de polialquileno y usos de éstos | |
| TW202039005A (zh) | 新穎之抑制細胞生長的整合素配體綴合物 | |
| TWI740910B (zh) | 非環抗病毒劑 | |
| JP2006522124A5 (enExample) | ||
| JP2008530124A (ja) | フラビウイルス感染症を処置または予防するための組成物および方法 | |
| JP2008523099A5 (enExample) | ||
| KR20170020923A (ko) | 표적화된 콘주게이트 및 입자 및 그것의 제형 | |
| CA2463284A1 (en) | Pyrimidine compounds and pharmaceutical compositions containing the compounds | |
| JP2021178820A (ja) | 脳癌の治療 | |
| JP2012526838A5 (enExample) | ||
| JP2006524711A5 (enExample) | ||
| JP2013542996A5 (enExample) | ||
| PT1615640E (pt) | Combinações antineoplásticas | |
| MX2008014520A (es) | Preparacion de conjugados polimericos de compuestos terapeuticos, agricolas, y de aditivos para alimentos. | |
| TW202033515A (zh) | 用於治療c型肝炎病毒之高活性藥物組合 | |
| KR20170120568A (ko) | 생리활성물질결합 블록 공중합체 | |
| JP2018529777A (ja) | Ｈｃｖの治療に対する併用療法レジメン | |
| JP2006508965A5 (enExample) | ||
| CA3204409A1 (en) | Novel benzotriazole derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase, and use thereof | |
| WO2024109964A1 (zh) | 一种口服载药胶束组合物及其制备方法 | |
| US10744209B2 (en) | Biodegradable polymeric nanoparticle conjugates and use thereof | |
| JP5843086B2 (ja) | 治療活性物質の作用を増強するための高分子化環状ニトロキシドラジカル化合物の使用 | |
| EP4580618A2 (en) | Pannexin-1 modulators and methods of treating disorders in which pannexin-1 is implicated |